It is FDA-approved to treat: EDS in adults and children 6 years and older with narcolepsy Cataplexy in adults with narcolepsy In adults, the most common side effects are nausea, anxiety ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Though narcolepsy is a rare condition, it occurs commonly enough, with type 1 affecting about one in 5,000 people. The diagnosis should be made by a sleep specialist who is able to apply the proper ...

The narcolepsy treatment market is set for substantial growth, with projections indicating an increase from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, reflecting a compound annual ...

Global Narcolepsy Treatment market to Grow at 5.1% CAGR ... Usage: Approved for improving wakefulness in adults with EDS due to narcolepsy or obstructive sleep apnea. Market Position: Expected ...

and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets ...

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category ... extend Buccolam's indication to include the treatment of epilepsy ...